Event-Driven Stocks

Inhibrx Biosciences, Inc.

INBXNasdaqCompleted

Spin-offSpun off from Sanofi S.A

The two companies

Parent
Sanofi S.A
↓ spun off ↓

Open either company's hub for its full SEC financials, ratios, ownership, filings, and every other event it's been part of.

Sector
Healthcare
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
State of incorporation
DE
Record date
May 17, 2024
Distribution date
May 29, 2024
Ratio
1:4
Parent sector
Form
10-12B/A
Filed
May 15, 2024

Financials — parent vs spin-off

SEC XBRL · latest year
Sanofi S.A

No XBRL financials available.

Inhibrx Biosciences, Inc.FY25
Revenue
$1M
Operating income
−$135M
Net income
−$140M
Total assets
$146M
Equity
$8M

Latest reported figures from each company's own SEC filings — the parent after the separation and the spin-off as a standalone. Full multi-year history on each company hub.

Spin-off signals

score 2/7 favorable · factors, not advice
  • Leverage (liabilities/assets)95%

    A heavy debt load loaded onto the spin-off is a known risk; a clean balance sheet is favorable.

  • Return on capital employed-119.8%

    EBIT ÷ capital employed — the quality metric the spin-off scorecard research weighs most.

  • Operating margin-10386.5%

    Profitability of the standalone business, from its own SEC filings.

  • Tax-basis reportNone found

    A Form 8937 (basis allocation) accompanies tax-free §355 spin-offs — favorable for taxable holders.

  • Insider buying (post-spin)None recorded

    Officers/directors buying their own newly independent shares (Form 4) has historically preceded outperformance.

  • Activist holder13D on file

    An activist with a 5%+ stake (Schedule 13D) is a potential value-unlock catalyst.

  • Time since spin-off2.0 years

    Studies find the spin-off return premium concentrates in roughly the first one to three years.

Factors the spin-off research literature (Greenblatt; Cusatis-Miles-Woolridge; Desai-Jain) associates with outcomes — computed from this company's own SEC filings, shown as factors, not a recommendation. The premium is debated and not guaranteed. How we compute these ↗

Filings & documents

Every entry traces to SEC EDGAR. The Information Statement is the primary source; the links below open the full filing and each company's complete filing history.